Literature DB >> 11105489

Reversal reactions in the skin lesions of AMFES patients: incidence and risk factors.

P Saunderson1, S Gebre, P Byass.   

Abstract

Reversal reactions affect the skin and/or nerves of leprosy patients. This paper looks at reversal reactions involving the skin in 594 new patients in central Ethiopia, followed for between 6 and 11 years after the start of treatment. The incidence of reversal reaction declines steadily after the start of treatment, but the first episode may occur as long as 5 years after diagnosis in both paucibacillary (PB) and multibacillary (MB) patients. Recurrent episodes occurred up to 6 years after diagnosis. PB patients were at greatest risk for reversal reaction in the first year after diagnosis and MB patients in the first 4 years. The highest incidence rate was 18 episodes per 100 person years in MB patients during the first year after diagnosis. The ratio of the incidence rates for the first 3 years in MB versus PB patients is 2.4 (95% CI 1.6-3.8). This study confirms that starting effective treatment and borderline classification are risk factors for reversal reactions. Pregnancy/delivery in the 6 months prior to diagnosis was a significant risk factor for presenting with a reversal reaction [relative risk (RR) 5.9 (95% CI 2.1-16.5)], but later pregnancies were not associated with an increased risk. Being female was a significant risk factor for the late appearance of the first episode of reversal reaction. Having a reversal reaction in the first year after diagnosis was a highly significant risk factor for the development of later reactions [RR in PB cases 11.9 (95% CI 3.4-41.7); in MB cases 6.4 (95% CI 3.8-10.6)]. Being HIV positive was a risk factor for developing recurrent reversal reactions, although only three out of 29 recurrent cases were HIV positive [RR 2.7 (95% CI 1.4-5.1)].

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105489     DOI: 10.5935/0305-7518.20000034

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  8 in total

1.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

2.  Development of Type 2, But Not Type 1, Leprosy Reactions is Associated with a Severe Reduction of Circulating and In situ Regulatory T-Cells.

Authors:  Ana Paula Vieira; Maria Ângela Bianconcini Trindade; Carla Pagliari; João Avancini; Neusa Yurico Sakai-Valente; Alberto José da Silva Duarte; Gil Benard
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

3.  Risk factors for leprosy reactions in three endemic countries.

Authors:  David M Scollard; Celina M T Martelli; Mariane M A Stefani; Maria de Fatima Maroja; Laarni Villahermosa; Fe Pardillo; Krishna B Tamang
Journal:  Am J Trop Med Hyg       Date:  2014-12-01       Impact factor: 2.345

4.  The DermLep Study I: Results of Prospective Nation-Wide Survey of the Number & Profile of Leprosy Patients seen by Dermatologists in India.

Authors:  P Narasimha Rao; Santoshdev Rathod; Sujai Suneetha; Sunil Dogra; Sunil Kumar Gupta; Rita Vora; Shushruth Kamoji; Swagta Tambe
Journal:  Indian Dermatol Online J       Date:  2020-09-19

5.  Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy.

Authors:  Pierre-Yves Bochud; Thomas R Hawn; M Ruby Siddiqui; Paul Saunderson; Sven Britton; Isaac Abraham; Azeb Tadesse Argaw; Marta Janer; Lue Ping Zhao; Gilla Kaplan; Alan Aderem
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

6.  Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy.

Authors:  P-Y Bochud; D Sinsimer; A Aderem; M R Siddiqui; P Saunderson; S Britton; I Abraham; A Tadesse Argaw; M Janer; T R Hawn; G Kaplan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-05-09       Impact factor: 3.267

7.  International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes.

Authors:  Ponnaiah Manickam; Sanjay M Mehendale; Bathyala Nagaraju; Kiran Katoch; Abdul Jamesh; Ramalingam Kutaiyan; Shen Jianping; Shivakumar Mugudalabetta; Vitthal Jadhav; Prabu Rajkumar; Jayasree Padma; Kanagasabai Kaliaperumal; Vijayakumar Pannikar; Padabettu Krishnamurthy; Mohan D Gupte
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

8.  Identifying Leprosy and Those at Risk of Developing Leprosy by Detection of Antibodies against LID-1 and LID-NDO.

Authors:  Francianne M Amorim; Maurício L Nobre; Leonardo C Ferreira; Larissa S Nascimento; Alesson M Miranda; Glória R G Monteiro; Kathryn M Dupnik; Malcolm S Duthie; Steven G Reed; Selma M B Jeronimo
Journal:  PLoS Negl Trop Dis       Date:  2016-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.